Design and Synthesis of Inhibitors of the E3 Ligase SMAD Specific E3 Ubiquitin Protein Ligase 1 as a Treatment for Lung Remodeling in Pulmonary Arterial Hypertension.
Duncan E ShawNichola SmithRene BeerliSimona CotestaPier-Luca D'AlessandroAnne-Marie EdwardsRene LattmannDimitrios LizosRobert PulzLisa RooneyBindi SohalCaroline RynnJessica TaylorThomas TroxlerGareth WilliamsSabine GuthDavid RowlandsPublished in: Journal of medicinal chemistry (2023)
Pulmonary arterial hypertension (PAH) is a devastating rare disease, which despite currently available treatments, still represents a high unmet medical need. Specific E3 ubiquitin protein ligase 1 (SMURF1) is a HECT E3 ligase that ubiquitinates key signaling molecules from the TGFβ/BMP pathways, which are of great relevance in the pathophysiology of PAH. Herein, the design and synthesis of novel potent small-molecule SMURF1 ligase inhibitors are described. Lead molecule 38 has demonstrated good oral pharmacokinetics in rats and significant efficacy in a rodent model of pulmonary hypertension.